Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    04638803
Previous Study | Return to List | Next Study

Microdose Pharmacokinetic Study of PRX-P4-003 In Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04638803
Recruitment Status : Recruiting
First Posted : November 20, 2020
Last Update Posted : May 18, 2021
Sponsor:
Information provided by (Responsible Party):
Praxis Bioresearch, LLC

Brief Summary:
The goal of the present study is to confirm in humans the in-vivo bioconversion of a Prodrug (PRX-P4-003) to (-)-fencamfamine (FCF) the active moiety when orally administered as a single microdose. A second component of the study will evaluate effect of food on pharmacokinetics of PRX-P4-003.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: PRX-P4-003, (-)-FCF Early Phase 1

Detailed Description:
A crossover study comparing blood concentrations after oral administration of microdoses of (-)-fencamfamine (FCF; 40 µg) or its prodrug form (PRX-P4-003; 100 µg)) in the fasted state will be carried out in 4 healthy male volunteers (Study A). This will be followed by determination of blood concentrations of (-)-fencamfamine in a separate cohort of 4 volunteers following oral administration of a microdose of PRX-P4-003 (100 µg) in a fed state (Study B).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: In the first arm a fixed order crossover of a PRX-P4-003 followed by administration of the (-)-FCF after a washout period. In the second arm a separate cohort will be administered PRX-P4-003 under fed conditions.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 0, Open-Label, Crossover Microdose Pharmacokinetic Study of PRX-P4-003 In Healthy Volunteers
Actual Study Start Date : February 25, 2021
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : October 31, 2021

Arm Intervention/treatment
Experimental: Crossover (fasted)
On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol, on Day 15 subjects are dosed with 40 µg of (-)-FCF. Both treatment will be administered under the fasted conditions.
Drug: PRX-P4-003, (-)-FCF
sequential study
Other Names:
  • Prodrug
  • Stimulant

Experimental: Single Group (fed)
On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol. The treatment will be administered under the fed condition.
Drug: PRX-P4-003, (-)-FCF
sequential study
Other Names:
  • Prodrug
  • Stimulant




Primary Outcome Measures :
  1. Outcome [ Time Frame: 24 hours ]
    Plasma (-)-FCF exposure (AUC 0-t) after Oral dosing of PRX-P4-003 and (-)-FCF



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Male age 18 to 45 years, participants must be willing to fast for 10 hours
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male aged 18 to 45 years. Willing to fast for at least 8 hours overnight and 4 hours after study drug dose (Study A).
  2. BMI within 18 - 32 kg/m2, inclusive.
  3. Willing/able to provide signed Informed Consent Form & HIPAA authorization for this study.
  4. Agreement to use a highly effective method of birth control with partners of childbearing potential during the study and for 1 month after study dosing such as, abstinence, barrier methods.
  5. Normal heart rate (50 to 100 bpm) and blood pressure (diastolic 60-85 mm Hg and systolic 90 to 130 mm Hg, inclusive) at Screening and Day 0.
  6. Nonsmoker or has not smoked within the past 6 months of Screening Visit 1 and throughout study participation. Use of recreational and/or medicinal marijuana are NOT permitted within 3 months prior to Screening and during the study. Marijuana use should not be initiated after Screening.
  7. Able to communicate well with the Investigator and to comply with the study procedures, requirements, restrictions, and directions of the clinic staff.

Exclusion Criteria:

Main Criteria for Exclusion:

Subjects who meet the following criteria are excluded from study participation

  1. History or presence of clinically significant respiratory, GI, renal, hepatic, hematological, neurological (including history of seizure), cardiovascular, psychiatric (including known addictive disorders), musculoskeletal, genitourinary, immunological, or dermatological disorders. The existence of any surgical or medical condition that, in the judgment of the clinical Investigator, might jeopardize the subject's safety, tolerability or interfere with the absorption, distribution, metabolism or excretion of the study drug.
  2. Any history of suicide attempts or current suicidal ideation.
  3. Abnormal clinically significant laboratory, physical, or neurological findings during screening.
  4. Abnormal and clinically significant ECG (as determined by the Investigator or his/her designee) at Screening or Day -0. Abnormalities include, but are not limited to, QTc interval (average of three ECGs) greater than or equal to 450 msec based on 12 lead ECG at Screening or Day -1. Subjects with a history of congenitally prolonged QT interval.
  5. In the 14 days (or 5 half-lives, whichever is longer) prior to dosing, the need for prescription medications.
  6. Use of acetaminophen greater than a single dose of 1000 mg up to 3 days prior to Day 1.
  7. Use of any investigational drug or medical device within 3 months prior to study admission.
  8. Known hypersensitivity to, or intolerance of, drugs with the same mechanism of action as PRX-P4-003 or (-)-fencamfamine.
  9. Donation or loss of greater than 500 mL of blood in the 8 weeks before dosing. or planned donation of blood at any time during trial participation.
  10. History of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) or drug addiction within the past 2 years, as determined by the Investigator. A positive urine drug, or positive alcohol urine (or breath) test at Screening or Day-1.
  11. Unwillingness to refrain from alcohol, or illicit or recreational drugs, within 24 hours prior to Day -1and during inpatient period.
  12. Seropositive for Hepatitis B, Hepatitis C, (tested during screening) or known HIV infection.
  13. The subject is unwilling or unable to comply with the protocol or scheduled appointments.
  14. The subject is unable to understand verbal or written English or any other language for which a certified translation of the approved informed consent is available.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04638803


Contacts
Layout table for location contacts
Contact: Kore Liow, MD 808-564-6141 kliow@hawaiineuroscience.com
Contact: Catherine Mitchell 808-564-6141 cmitchell@hawaiineuroscience.com

Locations
Layout table for location information
United States, Hawaii
Hawaii Pacific Neuroscience Recruiting
Honolulu, Hawaii, United States, 96817
Sponsors and Collaborators
Praxis Bioresearch, LLC
Investigators
Layout table for investigator information
Principal Investigator: Kore Liow, MD Hawaii Pacific Neuroscience
Layout table for additonal information
Responsible Party: Praxis Bioresearch, LLC
ClinicalTrials.gov Identifier: NCT04638803    
Other Study ID Numbers: PBR001
R44116764 ( Other Grant/Funding Number: NIMH )
First Posted: November 20, 2020    Key Record Dates
Last Update Posted: May 18, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Central Nervous System Stimulants
Physiological Effects of Drugs